Development and evaluation of an immuno-MALDI (iMALDI) assay for angiotensin I and the diagnosis of secondary hypertension

Clinical Proteomics

Christoph H Borchers¹  Daniel T Holmes²  Robert Popp³  Jessica Grace van der Gugten²  Alexander G Camenzind³ 

[1] Department of Biochemistry and Microbiology, University of Victoria, Victoria, BC V8P 5C2, Canada;Department of Pathology and Laboratory Medicine, St. Paul’s Hospital, University of British Columbia, 1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada;Genome British Columbia Proteomics Centre, University of Victoria, 3101-4464 Markham St, Victoria, BC V8Z 7X8, Canada

关键词: Immuno-MALDI;    iMALDI;    PRA;    Plasma renin activity;    Angiotensin-I;    Hypertension;   

Others  :  803370
DOI  :  10.1186/1559-0275-10-20

 received in 2013-09-20, accepted in 2013-11-13,  发布年份 2013

【 摘 要 】

Plasma renin activity (PRA) is an essential analytical tool for screening and diagnosis of secondary forms of hypertension. Typically, PRA is measured by competitive radioimmunoassay, but there are significant drawbacks to this technique including non-specificity, long analysis times, narrow calibration range, and the requirement for radionucleotides. In this paper, we report a method for plasma renin activity determination by immuno-MALDI mass spectrometry detection. This method overcomes the issues of non-specificity and long analytical times present with RIA, and does not require the use of radionucleotides. As an initial methodological evaluation, plasma renin activity results obtained by radioimmunoassay, LC/ESI-MS/MS, and immuno-MALDI on 64 samples from an outpatient primary aldosteronism screening program have been compared. A strong correlation was found between immuno-MALDI and radioimmunoassay (R² = 0.9412, 62/64 within the 95% CI of the Bland-Altman plot), and iMALDI and LC/ESI-MS/MS (R² = 0.9471, 62/64 within the 95% CI of the Bland-Altman plot). Technical replicates showed a 4.8% CV, while inter- and intra-day replicates showed CVs of 17.3% and 17.2% respectively. We have developed an assay capable of measuring PRA without the use of radionucleotides. This immuno-MALDI approach affords the specificity of MS while avoiding the long analytical run times and technical problems associated with HPLC. With the use of robotic sample preparation to optimize precision, this assay should be adaptable to clinical environments.

【 授权许可】

   
2013 Camenzind et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JLJ, Jones DW, Materson BJ, Oparil S, Wright JTJ, Rocella EJ: Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2009, 42:1206-1252.
• [2]Campbell DJ, Nussberger J, Stowasser M, Danser AHJ, Morgant A, Frandsen E, Ménard J: Activity assays and immunoassays for plasma renin and prorenin: information provided and precautions necessary for accurate measurement. Clin Chem 2009, 55:867-877.
• [3]Sealey JE: Plasma renin activity and plasma prorenin assays. Clin Chem 1991, 37:1811-1819.
• [4]Pickens PT, Bumpus FM, Lloyd AM, Smeby RR, Page IH: Measurement of renin activity in human plasma. Circ Res 1965, 17:438-448.
• [5]Kodish ME, Katz FH: Plasma renin concentration: comparison of angiotensinase inhibitors and correlation with plasma renin activity and aldosterone. J Lab Clin Med 1974, 83:705-715.
• [6]Poulsen K, Jorgensen J: An easy radioimmunological microassay of renin activity, concentration and substrate in human and animal plasma and tissues based on angiotensin I trapping by antibody. J Clin Endocrinol Metab 1974, 39:816-825.
• [7]Hubl W, Haussig K, Hofmann F, Büchner M, Rohde W, Dörner G: Enzyme immunoassay and radioimmunoassay for plasma renin activity. I. Comparison of the methods. Endokrinologie 1981, 77:333-340.
• [8]Miyazaki T, Kai M, Ohkura Y: Determination of renin activity in human plasma by column-switching high-performance liquid chromatography with fluorescence detection. J Chromatogr 1989, 490:43-51.
• [9]Young WF: Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf) 2007, 66:607-618.
• [10]Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WFJ, Montori VM: Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008, 93:3266-3281.
• [11]Dorrian CA, Toole BJ, Alvarez-Madrazo S, Kelly A, Connell JMC, Wallace AM: A screening procedure for primary aldosteronism based on the Diasorin Liaison automated chemiluminescent immunoassay for direct renin. Ann Clin Biochem 2010, 47(Pt 3):195-199.
• [12]Perschel FH, Schemer R, Seiler L, Reincke M, Deinum J, Maser-Gluth C, Mechelhoff D, Tauber R, Diederich S: Rapid screening test for primary hyperaldosteronism: ratio of plasma aldosterone to renin concentration determined by fully automated chemiluminescence immunoassays. Clin Chem 2004, 50:1650-1655.
• [13]Manolopoulou J, Bennett A, Grimminger P, Fischer E, Pallauf A, Diederich S, Reincke M, Bidlingmaier M: Ratio of Plasma Aldosterone to Plasma Renin (ARR) using two fully automated chemiluminescence immunoassays. Endocr Rev 2012, 33:SAT-226.
• [14]Trenkel S, Seifarth C, Schobel H, Hahn EG, Hensen J: Ratio of serum aldosterone to plasma renin concentration in essential hypertension and primary aldosteronism. Exp Clin Endocrinol Diabetes 2002, 110:80-85.
• [15]Ferrari P, Shaw SG, Nicod J, Saner E, Nussberger J: Active renin versus plasma renin activity to define aldosterone-to-renin ratio for primary aldosteronism. J Hypertension 2004, 22:377-381.
• [16]Wedatilake YN, Scanlon MJ, Barnes SC: The clinical utility of two renin mass methods to detect primary hyperaldosteronism compared with renin activity. Ann Clin Biochem 2011, 48(pt 3):256-262.
• [17]Letavernier E, Peyrard S, Amar L, Zinzindohoué F, Fiquet B, Plouin PF: Blood pressure outcome of adrenalectomy in patients with primary hyperaldosteronism with or without unilateral adenoma. J Hypertension 2008, 26:1816-1823.
• [18]Rossi GP, Barisa M, Belfiore A, Desideri G, Ferri C, Letizia C, Maccario M, Morganti A, Palumbo G, Patalano A, et al.: The aldosterone-renin ratio based on the plasma renin activity and the direct renin assay for diagnosing aldosterone-producing adenoma. J Hypertension 2010, 28:1892-1899.
• [19]Ahmed AH, Gordon RD, Taylor PJ, Ward G, Pimenta E, Stowasser M: Are women more at risk of false-positive primary aldosteronism screening and unnecessary suppression testing than men? J Clin Endocrinol Metab 2011, 96:E340-E346.
• [20]Fyhrquist F, Saijonmaa O: Plasma renin activity: an assay with ongoing clinical relevance. Clin Chem 2008, 54:1400.
• [21]Fredline VF, Kovacs EM, Taylor PJ, Johnson AG: Measurement of plasma renin activity with use of HPLC-electrospray-tandem mass spectrometry. Clin Chem 1999, 45:659-664.
• [22]Bystrom CE, Salameh W, Reitz R, Clarke NJ: Plasma renin activity by LC-MS/MS: development of a prototypical clinical assay reveals a subpopulation of human plasma samples with substantial peptidase activity. Clin Chem 2010, 56:1561-1569.
• [23]Grebe SK, Singh RJ: LC-MS/MS in the clinical laboratory - where to from here? Clin Biochem Rev 2011, 32:5-31.
• [24]Bizzini A, Durussel C, Bille J, Greub G, Prod’hom G: Performance of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of bacterial strains routinely isolated in a clinical microbiology laboratory. J Clin Microbiol 2010, 48:1549-1554.
• [25]Seng P, Drancourt M, Gouriet F, La Scola B, Fournier PE, Rolain JM, Raoult D: Ongoing revolution in bacteriology: routine identification of bacteria by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clin Infect Dis 2009, 49:543-551.
• [26]Dhiman N, Hall LH, Wohlfiel SL, Buckwalter SP, Wengenack NL: Performance and cost analysis of matrix-assisted laser desorption ionization-time of flight mass spectrometry for routine identification of yeast. J Clin Microbiol 2011, 49:1614-1616.
• [27]Jiang J, Parker CE, Hoadley KA, Perou CM, Boysen G, Borchers CH: Development of an immuno tandem mass spectrometry (iMALDI) assay for EGFR diagnosis. Proteomics Clin Appl 2007, 1:1651-1659.
• [28]Jiang J, Parker CE, Fuller JR, Kawula TH, Borchers CH: An immunoaffinity tandem mass spectrometry (iMALDI) assay for detection of francisella tularensis. Anal Chim Acta 2007, 605:70-79.
• [29]Reid JD, Holmes DT, Mason DR, Shah B, Borchers CH: Towards the development of an immuno MALDI (iMALDI) mass spectrometry assay for the diagnosis of hypertension. J Am Soc Mass Spectrom 2010, 21:1680-1686.
• [30]Mason DR, Reid JD, Camenzind AG, Holmes DT, Borchers CH: Duplexed iMALDI for the detection of angiotensin I and angiotensin II. Methods 2012, 56:213-222.
• [31]Van Der Gugten JG, Holmes DT: Plasma renin activity by tandem mass spectrometry employing analyte immunoprotection. In Presented at the 60th Annual Conference on Mass Spectrometry and Allied Topics, May 20 - May 24. Vancouver, BC, Canada; 2012.
• [32]Tholen DW, Kallner A, Kennedy JW, Krouwer JS, Meier K: Evaluation of precision performance of quantitative measurement methods; approved guideline—second edition. Evaluation 2004., 24(25)
• [33]Speicher KD, Kolbas O, Harper S, Speicher DW: Systematic analysis of peptide recoveries from in-gel digestions for protein identifications in proteome studies. J Biomol Tech 2000, 11:74-86.
• [34]Drayer JI, Benraad TJ: The reliability of the measurement of plasma renin activity by radioimmunoassay. Clin Chim Acta 1975, 61:309-324.
• [35]Anderson NL, Razavi M, Pearson TW, Kruppa G, Paape R, Suckau D: Precision of heavy-light peptide ratios measured by MALDI-tof mass spectrometry. J Proteome Res 2012, 11:1868-1878.
• [36]Sealey JE, Laragh JH: Searching out low renin patients: limitations of some commonly used methods. Am J Med 1973, 55:303-314.
• [37]Fyhrquist F, Soveri P, Puutula L, Stenman UH: Radioimmunoassay of plasma renin activity. Clin Chem Lab Med 1976, 22:250-256.
• [38]BioMérieux receives FDA clearance for vitek MS clinical microbiology system http://www.genomeweb.com/proteomics/biomerieux-receives-fda-clearance-vitek-ms-clinical-microbiology-system webcite, August 22, 2013. Access date: November 17, 2013
• [39]Goodfriend TL, Levine L, Fasman GD: Antibodies to Bradykinin and Angiotensin: a use of carbodiimides in immunology. Science 1964, 144:1344-1346.
• [40]Kuzyk MA, Smith D, Yang J, Cross TJ, Jackson AM, Hardie DB, Anderson NL, Borchers CH: Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol Cell Prot 2009, 8:1860-1877.
• [41]cpR chemical pathology interface for R: a graphical user interface to R for use in clinical chemistry http://sourceforge.net/p/cprchempath/wiki/Home/ webcite Administrator: dtholmes. Access date: November 17, 2013